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Abstract

ROLE OF ROK AND PKC IN PERMEABILIZED FEMORAL ARTERIAL
SMOOTH MUSCLE

By Lyndsay Jacquelyn Clelland, B.S.

A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2007
Director: Paul H. Ratz, Ph.D.
Professor, Department of Biochemistry and Pediatrics

Discoveries made with KCl-induced contractions have elucidated the more
complex reactions involved in GPCRs signaling; once the mechanisms of smooth muscle
Ca2+ sensitization and desensitization are fully understood, then the development of
advanced treatments for vascular disorders such as hypertension, cerebral and coronary
vasospasm, and vascular hyporeactivity following hemorrhagic shock may be possible.
Studies have shown that KCl-induced contractions induce Ca2+-sensitization. Therefore,
we tested the hypothesis that KCl induced Ca2+-sensitization is due to ROK activation by
the increase in [Ca2+]i . To test this hypothesis, rabbit femoral arteries were permeabilized
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with 20µg/ml α-toxin and 1% Triton X-100 and subjected to different calcium
concentrations in the presence or absence of various ROK inhibitors. For a comparison
we also used various PKC and MLCK inhibitors and repeated these experiments in intact
tissues. We found that either [Ca2+]i alone does not directly activate ROK or the
permeabilization technique itself disrupts the normal ROK signaling system. Secondary
findings revealed that α-toxin activates PKC pathways; in both chemically permeabilized
preparations proteases also appear to be activated and MLCK is the primary kinase
responsible for contraction.

INTRODUCTION

1.1 Basic Smooth Muscle Physiology
The development of force in smooth muscle, similar to cardiac and skeletal
muscles, involves the hydrolysis of adenosine triphosphate (ATP), actin-myosin crossbridge cycling, and the transient elevation of intracellular calcium ([Ca2+]i). Although the
three types of muscle possess similar properties, there are several structural and
functional differences unique to smooth muscles.
Smooth muscle is typically found lining hollow organs such as blood vessels, the
urinary bladder, airways and the gastrointestinal tract. In these and other systems, the
smooth muscle functions in a highly coordinated fashion to develop force either to
provide motility or to alter organ dimensions. For this reason, smooth muscle can be
classified into two broad categories based on the type of contraction it exhibits, phasic or
tonic. Phasic smooth muscles can cycle through relaxed and contracted phases, and are
responsible for processes such as peristalsis. On the other hand, tonic smooth muscles are
capable of sustaining contractions for long periods of time, allowing the tissue to
withstand imposed loads such as those found in the vascular system.
Tonic arterial smooth muscle must tolerate sustained contractions against imposed
loads for long periods of time without fatigue. This is possible, in part, because of a

1

2
highly developed and efficient economy of ATP use. Despite more than two decades of
work, the precise molecular mechanisms involved in the regulation of tonic force
maintenance remain to be determined. One model developed to explain high force
maintenance at a high energy economy is the latch bridge model (Figure 1), in which
dephosphorylation of attached crossbridges produce an attached crossbridge that detaches
much more slowly than a phosphorylated crossbridge (Hai and Murphy 1988; Ratz, Hai
et al. 1989). This proposed dephosphorylated, slowly detaching crossbridge was termed a
latch-bridge (Dillon, Aksoy et al. 1981). Recent evidence that dephosphorylated
crossbridges release ADP very slowly supports the latch-bridge model (Somlyo,
Khromov et al. 2004). Evidence from our laboratory indicates that tonic force
maintenance can be selectively attenuated by inhibition of rhoA kinase (ROK), and that
such attenuation is independent of changes in cellular free calcium levels ([Ca2+]i)
(Urban, Berg et al. 2003). Thus, tonic force maintenance is highly dependent on ROK
activity.
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A + Mp
pi

ATP
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cycling
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ADP
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Tonic tension

{
Figure 1: Schematic of the latch-bridge model (modification of Hai-Murphy Model). A
latch-bridge is formed when an attached crossbridge is desphosphorylated. The latchbridge detaches much more slowly than a crossbridge. A, Actin (thin filament); Mp,
phosphorylated Myosin (thick filament); AMp, attached Actin and phosphorylated
Myosin (cross-bridge cycling); AM, attached Actin and unphosphorylated Myosin (latchbridge formation); ATP, Adenosine Triphosphate; ADP, Adenosine Diphosphate; pi,
phosphate. }

Another distinguishable attribute of smooth muscle physiology, as compared to
skeletal and cardiac muscle, is the absence of troponin. In cardiac and skeletal muscle the
transient increase in [Ca2+]i binds directly to the protein troponin causing it to undergo a
conformational change. This change exposes the globular actin molecules of the thin
filament to the myosin heads of the thick filament. In the presence of ATP, crossbridge
cycling may then occur, developing force. This process is different in smooth muscle.
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In smooth muscle, the globular actin binding sites of the thin filament are not
blocked by troponin, but may be blocked by the thin filament binding proteins, calponin
and caldesmon (Earley, Su et al. 1998; Gusev 2001). Regardless, smooth muscle
crossbridges, unlike striated muscle crossbridges, must be phosphorylated on the 20 kDa
light chain of myosin (MLC) to be activated (Kamm and Stull 1985). That is, in order for
actin and myosin to bind and go through the crossbridge cycling to developing force,
MLC must be phosphorylated (Trybus 1989). Therefore, the MLC acts as a switch; when
the MLC is phosphorylated, the muscle is capable of undergoing contraction, and when
the MLC is not phosphorylated, it may not undergo contraction.

1.2 Phosphorylated Myosin Light Chain ratio
The level of MLC phosphorylation, as the fundamental determinate of tonic smooth
muscle contraction, is regulated by a complex series of events leading to either its
phosphorylation or dephosphorylation. Myosin light chain kinase (MLCK) is responsible
for phosphorylating MLC, turning it “on”; and myosin light chain phosphatase (MLCP)
is responsible for dephosphorylating MLC, turning it “off” (Kamm and Stull 1985;
Somlyo, Wu et al. 1999). The balance between these two proteins is important in the
regulation of smooth muscle contraction and can be described as the MLCK/MLCP ratio;
whereas a ratio greater than one would indicate a contraction and a ratio less than one
would indicate a less contracted state.
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Smooth muscle MLCK is activated by an increase in [Ca ]i, and this is why
[Ca2+]i has been attributed as the fundamental regulator of smooth muscle cells (Kamm
and Stull 1985). As [Ca2+]i levels rise, calcium binds to free intracellular calmodulin
(CaM) forming a calcium-calmodulin complex (Ca-CaM); Ca-CaM binds to and activates
MLCK. Other kinases may serve the same role, because a recent study using MLC kinase
knockout (-/-) mice shows that arteries still contract (Somlyo, Wang et al. 2004).
However, MLCK is considered to be the main kinase involved in the phosphorylation of
the 20 kDa MLC.
Smooth muscle MLCP consists of three subunits. The 37 kDa catalytic subunit
falls in the type 1 class of protein phosphatases (PP1c-delta) (Alessi, MacDougall et al.
1992; Gong, Cohen et al. 1992; Mitsui, Inagaki et al. 1992; Johnson, Cohen et al. 1997)
and is responsible for dephosphorylating MLC. The catalytic subunit is activated and
targeted to the substrate by myosin phosphatase targeting subunit (MYPT) (Hartshorne,
Ito et al. 1998), and has a molecular weight of 110-120 kDa (Johnson, Cohen et al. 1997).
The third subunit 21 kDa (Johnson, Cohen et al. 1997), (M20) binds to MYPT and has no
defined function (Hartshorne, Ito et al. 1998). MLCP activity can be negatively regulated
by its phosphorylation and by association with inhibitor proteins.

1.3 Calcium Regulation
It has long been known that calcium is responsible for the contraction of muscles.
Although the transient increase in [Ca2+]i has different effectors in the different types of

6
muscle, its necessity for contraction remains constant. For this reason, the study of
calcium has been critical to the understanding of arterial smooth muscle physiology
(Morgan and Morgan 1982; van Breemen, Chen et al. 1995; Karaki 2004).
Studies have shown that in tonic arteries the resting [Ca2+]i is approximately
100nM in the rat femoral artery (Van Heijst, Blange et al. 2000) and 106+8nM in the rat
pulmonary artery (Somlyo and Himpens 1989). Whereas the outside resting calcium level
is approximately 1.5mM in the rat femoral artery (Van Heijst 2000). This balance of
calcium concentrations is maintained by multiple membrane-based Ca2+ channels,
pumps, compartments and intracellular buffers (Ratz 2005).
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Figure 2: Schematic diagram of calcium entry into the cell. Modified figure (see review
Ca2+ {Ratz, 2005}). Intracellular calcium is highly regulated by multiple membrane
based channels, pumps, and compartments. Calcium is pumped from the intracellular
matrix into the Sarcoplasmic Reticulum (SR) or out of the cell. Upon stimulation,
channels open allowing for an influx of calcium. VOCC, Voltage operated calcium
channel; SOCC, Store operated calcium channel; ROCC, Receptor operated calcium
channel; SR, Sarcoplasmic reticulum. IP3, Inositol tri-phosphate.}
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1.4 Calcium Sensitization
In addition to the dependency on increases in [Ca2+]i for activation of contraction,
studies as early as 1984 recognized that activation of smooth muscle G protein-coupled
receptors (GPCR) by stimuli such as norepinephrine can produce greater increases in
force for a given increase in [Ca2+]i than does activation of muscle by KCl (Morgan and
Morgan 1984; DeFeo and Morgan 1985; Bradley and Morgan 1987; Karaki, Sato et al.
1988; Rembold and Murphy 1988; Sato, Ozaki et al. 1988; Gerthoffer, Murphey et al.
1989; Ozaki, Sato et al. 1989; Himpens, Kitazawa et al. 1990). These results are
supported by data obtained from Ca2+-clamped (permeabilized) tissues showing that, at
constant Ca2+ concentrations, cyclic nucleotides can induce relaxation (Ruegg and Paul
1982; Ruegg and Pfitzer 1985), and stimuli activating contractile GPCRs can elevate
force (Kitazawa 1988; Nishimura, Kolber et al. 1988; Kobayashi, Kitazawa et al. 1989;
Himpens, Kitazawa et al. 1990) concomitant with increases in MLC phosphorylation
(Kitazawa, Gaylinn et al. 1991). Thus, the degree of sensitivity of smooth muscle
contractile proteins to increases in [Ca2+]i is a regulated parameter. Importantly, Ca2+
sensitivity appears to play as important a role in regulation of smooth muscle contraction
as does increases in [Ca2+]i alone (reviewed by (Savineau and Marthan 1997; Hori and
Karaki 1998; Somlyo and Somlyo 1998; Pfitzer 2001; Kawano, Yoshimura et al. 2002;
Somlyo 2003)).
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1.5 GPCR and their Role in Calcium Sensitivity
Several mechanisms are involved in regulating calcium sensitivity, such as the
modulation of MLCK activity, mechanisms involving thin filament regulation, and
possible regulation by heat shock proteins. However, calcium sensitivity is primarily
regulated at the level of MLC phosphorylation by modulation of MLCP activity
(Kitazawa, Gaylinn et al. 1991; Kitazawa, Masuo et al. 1991; Kubota, Nomura et al.
1992).
MLCP activity is largely regulated by G protein coupled receptors linked to one
of two identified trimeric G proteins, Gq and G12/13 (Somlyo 2003). The activation of
these G proteins leads to the generation of multiple second messengers which result in the
downstream inhibition of MLCP (Figure 3). Therefore, most of the upstream signals
generated upon GPCR stimulation, including ROK and PKC, are regulated at the plasma
membrane although the motor proteins responsible for generation of force reside in the
cell interior (Ratz 2005).
The GPCR associated with the trimeric Gq protein are stimulated by many
activators such as: acetylcholine [muscarinic M1], Α1-adrenergic agonists, angiotensin II,
ATP [P2x and P2y], histamine [H1], platelet-derived growth factor (PDGF), serotonin [5HT-1c], thyrotropin-releasing hormone (TRH) and vasopressin. Once stimulated, the Gq
protein triggers a cascade of activity beginning with the activation of phospholipase C
beta (PLCβ) followed by the activation of phosphatidylinositol di-phosphate (PIP2). PIP2
is broken into two components, inositol 1,4,5-triphosphate (IP3) stimulating calcium
release from the SR and diacylglycerol (DAG) activating, with the aid of intracellular
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calcium, protein kinase C (PKC). PKC phosphorylates a 17-kDa PKC-activated
phosphatase inhibitor (CPI-17) on the Thr38 site. Phosphorylated CPI-17 binds to and
inhibits MLCP.
As with the trimeric Gq protein, the GPCR associated with trimeric G12/13 protein,
also triggers a cascade of events upon stimulation. Some of those factors responsible for
activation include: Ca2+ calmodulin-dependent protein kinases (CaMKI to IV), cAMP
phosphodiesterase, MLCK, NAD+ kinase, nitric oxide synthase, phosphoinositide 3kinase and plasma membrane Ca2+- ATPase (Ca2+ pump). Once stimulated, the trimeric
G12/13 protein activates the low molecular weight GTPase, rhoA. RhoA recruits rhoA
Kinase (ROK) to the plasma membrane and activates it. ROK may then phosphorylate
either one of two myosin phosphatase targeting subunits (MYPT1-Thr696 or MYPT1Thr653) associated with MLCP, resulting in inhibition.
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Figure 3: Schematic diagram of G-protein coupled receptors. MLCP is inhibited by CPI17 and ROK. Two identified trimeric G proteins are responsible: Gq activates CPI-17 and
G12/13 activates ROK. α,β,γ, subunits of the trimeric G protein; GTP, guanosine
triphosphate; GDP, guanosine diphosphate; GDI-RhoA-GDP, inactive rhoA GTPase;
RhoA-GTP, active rhoA GTPase; ROK, RhoA Kinase; PLCβ, phospholipase C beta;
PIP2, phosphatidylinositol di-phosphate; IP3, inositol 1,4,5-triphosphate; DAG,
diacylglycerol; PKC, protein kinase C; CPI-17, 17-kDa PKC-activated phosphatase
inhibitor}
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1.6 Plasma Membrane
The smooth muscle plasma membrane contains receptors, channels and pumps
that are necessary for the downstream regulation of contraction. Not only does the plasma
membrane contain the GPCRs, Gq and G12/13, regulating MLCP, it is also hypothesized
that the ROK is activated at the plasma membrane (Ratz 2005).
The smooth muscle plasma membrane contains several domains. One these
domains include caveolae, which have been recently called into interest for their role in
the regulation of smooth muscle contraction. Caveolae are small 50-100 nm cave-like
invaginations of the plasma membrane housing a unique lipid domain that contains high
concentrations of cholesterol and sphingolipids (Smart, Graf et al. 1999) and display an
alternating pattern when viewed using immunohistochemical fluorescence-labeling of
selected proteins (North, Galazkiewicz et al. 1993; Tanaka, Hijikata et al. 2001;
Hagiwara, Nishina et al. 2002). Several studies support the hypothesis that GPCR
stimulation increases translocation of inactive cytosolic rhoA (bound to rhoA-GDI) to
peripheral, plasma membrane sites such as caveolae, where rhoA-GTP activates ROK
(Fujihara, Walker et al. 1997; Gong, Fujihara et al. 1997; Taggart, Lee et al. 1999),
supporting a caveolar role in regulation of Ca2+ sensitization (Taggart 2001). Moreover,
the hypothesis that caveolae play an important role in GPCR-induced contraction is
supported by data showing that disruption of the caveolar structure with the cholesteroldepleting agent, methyl-β-cyclodextrin, or by caveolin-1 knockout, reduces the ability of
some GPCR stimuli, but not KCl, to produce contraction (Drab, Verkade et al. 2001;
Dreja, Voldstedlund et al. 2002; Je, Gallant et al. 2004)(see Ratz review ((Ratz 2005)).
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1.7 Membrane Depolarization with KCl and KCl-induced Ca Sensitization
High potassium physiological saline solutions are frequently used in the
laboratory to depolarize smooth muscles cells, opening VOCCS, allowing for an influx of
calcium, an increase in [Ca2+]i and force development. This technique is based on the
well accepted premise that increases in [Ca2+]i is the fundamental regulator of smooth
muscle cell contraction (Karaki 2004).
There are several benefits to using this technique to elicit a contraction in smooth
muscles. The use of high K+ bypasses the complex mechanisms involved in GPCR
activation of smooth muscles. For example, KCl, unlike stimuli that activate Gq, does not
activate PLC and cause an increase in inositol triphosphate levels (Ratz 1990). As noted,
the GPCR pathways involve many second messengers to activate series of reactions. The
direct increase in [Ca2+]i by membrane depolarization provides simplicity to an otherwise
complex mechanism. The ease of this technique also makes it highly reproducible.
In addition to simplicity and reproducibility, the benefits of high K+ in the study
of smooth muscle cells are extensive. High K+ has been used in comparative studies to
help understand the complex mechanisms of GPCR activation, to understand the
relationship between calcium and force, and has shed a great deal of light onto the subject
of calcium sensitization (Karaki, Sato et al. 1988). Because KCl was originally thought to
act solely by causing elevations in [Ca2+]i, the discovery by several laboratories,
including our own, that KCl can cause Ca2+ sensitization, was somewhat surprising.
There is strong evidence for participation of ROK in the regulation of KCl-induced
calcium sensitization. Whether or not PKC plays a role remains to be determined. Also,
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precisely how KCl causes Ca -sensitization remains to be determined. The two primary
2+

possible mechanisms include Ca2+-induced Ca2+ -sensitization, and depolarizationinduced Ca2+ sensitization.

1.8 Permeabilization
Permeabilization of smooth muscles has been a valuable technique for the direct
control of cytoplasmic solute composition and, consequently, for our understanding of
contractile regulation (Kitazawa, Kobayashi et al. 1989). Additionally, researchers have
been using this technique of chemically skinning smooth muscle in order to clamp
calcium to better understand Ca2+-sensitization (Anabuki, Hori et al. 2000; Sward, Dreja
et al. 2000; Takeuchi, Kushida et al. 2004; Durlu-Kandilci and Brading 2006).
There are currently four different detergents used today to chemically
permeabilize tissues: saponin, β-escin, α-toxin and Triton X-100. Saponin is known to
complex with cholesterol molecules in the surface membranes of cells to form pores
approximately 9 nm in diameter (Bangham, Horne et al. 1962) and found to uncouple the
receptors involved in physiological activation of smooth muscle (Kitazawa, Kobayashi et
al. 1989). β-escin retains surface receptor coupling (Kobayashi, Kitazawa et al. 1989),
and compared to saponin, has been found to have a milder action on the surface
membrane and is a more potent modifier of SR function (Launikonis and Stephenson
1999). In contrast, α-toxin is much milder than these two agents forming pores permeable
to molecules of up to 3kDa; and has been found to develop maximal force upon α-
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adrenergic stimulation, retain receptor activation (Kitazawa, Kobayashi et al. 1989) and
retain SR coupling. Finally, Triton X-100 leads to an extensively permeabilized cell in
which all membrane functions are eliminated including the loss of receptor and SR
coupling; and loses responsiveness to PKC activators (Kitazawa, Takizawa et al. 1999)

1.9 Objective
As demonstrated, the use of KCl to induce smooth muscle contraction in the
laboratory is very common and effective and it has been shown that KCl-induced
contraction induces Ca2+- sensitization. Once the cell signaling and contractile protein
regulatory systems induced by KCl are completely mapped, responses to KCl can quite
accurately be applied for comparison to more fully understand the vastly more complex
GPCR-induced regulation of smooth muscle contraction (Ratz 2005). Therefore, the
objective of this project was to test the hypothesis that KCl-induced calcium sensitization
reflects Ca2+-induced calcium sensitization by measuring the effect of selective ROK
inhibition on Ca2+-dependent contractions induced in chemically permeabilized isolated
femoral artery rings.

MATERIALS AND METHODS

2.1 Tissue Preparation
Tissues were prepared as previously described (Ratz 1993). Adolescent male and
female New Zealand White rabbits were anesthetized and then injected with
pentobarbital as approved by the Medical College of Virginia at Virginia Commonwealth
University Institutional Animal Care and Use Committee protocol #0305-3208l. Femoral
arteries were immediately removed and placed in cold (4°C) normal physiological saline
solution (NPSS; in mM: 140 NaCl, 4.7 KCl, 2.0 morpholino-propanesulfonic acid
(MOPS), 0.02 Na2ethylenediamine tetraacetic acid (EDTA) -to chelate trace heavy
metals, 1.2 Na2HP04•7H2O, adjusted to pH 7.4 with 5M NaOH at 37°C, 1.2 MgCl2, 1.6
CaCl2 and 5.6 α-D-glucose)). High-purity (18.2 MΩ) deionized water was used
throughout the study. Fat and adventitia were removed mechanically under a binocular
dissecting microscope (Olympus SZX12 or Zeiss 10093), and the endothelium was
removed by gently rubbing of the intimal surface with a rough metal rode approximately
the size of the arterial lumen diameter. The arteries were cut into 2-3 mm-wide rings.
Tissues were stored for no more than four days, covered at 4°C in NPSS.
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2.2 Isometric Force
Contractile force (F) was measured as previously described (Ratz 1993). Each
artery ring was suspended in an aerated 5ml tissue bath (Figure 4)(Myograph System610M -Danish Myo Technology, Denmark) between two stainless steel pins, attached to
a micrometer and isometric force transducer for length adjustments and force
measurements, respectively. The bath contained cold (4°C) NPSS. Voltage signals from
the Myograph were digitized and visualized on a computer screen as F (in g). Data were
acquired through an analog-digital converter board (National Instruments) and analyzed
using DASYLab (DasyTech, Amherst, NH)(Figure 5). Following a warm-up period and
L0 determination, the tissues were ready to undergo permeabilization without any further
length changes. All solutions were kept at 37°C prior to permeabilization.
All tissues underwent the standard “wake-up” and L0 determination before
experimentation occurred.

2.2.1. Raw Data
All raw data is presented in grams of force and the graphical models mimic actual
force tracing (Figures 6 & 7). These include the “wake-up” and L0 contractions in the
intact tissue, as well as the “wake-up” contraction in permeabilized tissues. Statistics
were not performed on raw data.
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Figure 4: Diagram from the Myograph System-610M owners manual. This system
allows for temperature and aeration control, length adjustments, isometric force
measurements and easy solution changes. Following mounting and equilibration, the
passive length-tension relationships of the vessels are determined, in the normalization
procedure. This ensures reproducibility among the segments and between experiments.
During the actual experiments, the circumference of the vessel is kept constant, i.e. the
vessels are examined under isometric conditions. Compounds are added directly to the
chamber and vessel tension is measured for contractile or relaxing effects of the tested
compound. }
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{
Figure 5: Tissue Bath- Myograph System-610 M (Photo taken from the owners manual).
The artery ring is suspended between two stainless steel pins, attached to a micrometer
and isometric force transducer.}

2.2.2. Standard Warm-up & Tissue “Wake-Up”
The tissues warmed for 45 minutes to 1 hour at 37°C in aerated NPSS until the
bath temperature reached 37°C. The myograph system was calibrated with the DASYLab
software (Force Calibration Kit -Danish Myo Technology, Denmark) following warm-up.
The tissues were then stretched to 0.5 grams of force and allowed to relax for 5
minutes and the process was repeated. Following the second stretch and relaxation, NPSS
was replaced with a high potassium solution (KPSS; NPSS in which 110 mM KCl was
substituted isosmotically for NaCl) for 5 minutes to elicit a contraction, washed twice
with NPSS and allowed to relax for 10 minutes. This process was repeated two more
times. Following the third KPSS contraction, the last 30 seconds of the contraction was
measured for the average maximal force (FT) (Figure 6).
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2.2.3. L0 Determination
The muscle length for which active force was maximum (L0) was determined for
each tissue using an abbreviated length-tension curve (Herlihy and Murphy 1973; Ratz
and Murphy 1987). Previous studies in Dr. Ratz’s lab have found that a passive (Fp) to
active (FA = FT - Fp) ratio of 0.13 + 0.03, is the standard L0 for the rabbit femoral artery.
This process involved stretching the tissues by 0.5 gram force increments every
five minutes until they reached 2 grams of force, releasing the tissue down to the
calculated passive force value and immediately contracting with KPSS for five minutes.
Stretching to 2 grams of force and rapidly releasing the length allows for the breaking of
attached latch bridges and an accurate passive force measurement. The calculated passive
force value is estimated by the following formula, ((FT * 0.13)/1.13), where 1.13 is an
adjustment factor due to the fact that FT and not FA was used in the calculation.
Following contraction the artery rings were washed twice with NPSS, and relaxing for
ten minutes in the NPSS. The FT was measured and the process was repeated once more
or until the Fp/FA values were in range (Figure 6).
In the Intact Tissue- KCl Induced Contraction (see section 3.1) tissue preparation,
1µM phentolamine was used to block α-receptor agonists during the L0 determination.
Phentolamine was not used in any other L0 determination.
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Figure 6: Wake-Up and L0 determination. Following warm-up in normal physiological
saline solution (NPSS) tissues were stretched to 0.5 grams of force two times, resting for
five minutes in between each stretch. Following the second stretch, the tissues were
contracted with high potassium saline solution (KPSS) for five minutes. Following the
contraction, tissues were washed twice with NPSS and allowed to rest for ten minutes.
This wake-up process was repeated two additional times. L0 determination is similar to
the wake-up except the tissues are stretched by 0.5 grams of force at five minute intervals
until 2 grams of force is reached. Length is then released to a calculated value
corresponding to the ideal passive force. Tissues are then contracted with KPSS for five
minutes, washed twice with NPSS, then allowed to relax for ten minutes. This process is
repeated at least one more time or until the passive to active force ratio is 0.13 + 0.03.}
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2.3 KCl-induced Contraction in Intact Tissue
Following L0 determination, the femoral artery rings were washed twice with a
NPSS and allowed to completely relax. The drug inhibitors were then added to three of
the four chambers and incubated for 20 minutes, the fourth chamber acted as the control.
After drug incubation, the solutions were switched to KPSS containing the same drug
inhibitors and allowed to contract for minimum of ten minutes. Raw data were collected
and normalized before statistics were run.

2.4 Calcium Response Curve- Intact Tissue
Following L0 determination, the femoral artery rings were washed twice with a
nominally calcium-free physiological saline solution (0Ca-NPSS; NPSS without Ca2+
added), and allowed to rest for ten minutes. The artery rings were then treated with a high
potassium nominally calcium-free physiological saline solution (0Ca-KPSS; KPSS
without Ca2+ added) for five minutes and then washed with 0Ca-NPSS. The drug
inhibitors were then added to three of the four chambers and incubated for 20 minutes,
the fourth chamber acted as the control. After drug incubation, the solutions were
switched to 0Ca-KPSS containing the same drug inhibitors and allowed to rest for five
minutes. A calcium concentration-response curve (0.10mM – 2.00mM) was constructed
by adding a specific amount of 0.1M Ca2+ -KPSS stock solution (0Ca-KPSS with 1M
CaCl2 stock solution added). Raw data were collected and normalized before statistics
were run.
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2.5 Tissue Permeabilization
Artery rings at L0 were washed with a calcium-free solution, “relaxing solution”
(RS; in mM: 74.1 potassium methanesulphonate, 4.0 magnesium methanesulphonate, 4.0
Na2ATP, 4.0 EGTA, 5.0 creatine phosphate, and 30.0 PIPES (adjusted to pH 7.1 with 1N
KOH and ionic strength was kept constant at 0.18 with additional 0.5M potassium
methansulfonate)), and then subject to chemical permeabilization by either 20 µg/ml αtoxin or 1% Triton X-100 (See 2.5.1 & 2.5.2).

2.5.1. Permeabilizing with Alpha Toxin & “Wake-Up”
RS was replaced with 20µg/ml α-toxin, enough to cover the tissue, for 30 minutes
at 30°C and continued for 20 minutes at 25°C in RS with the addition of 10µM A23187
(to deplete SR calcium). Following permeabilization the tissues were washed thoroughly
with RS to remove the α-toxin and held at 30°C.
In order to “wake-up” the artery rings following permeabilization, the tissues
were contracted three times with a free calcium concentration of pCa = 6.5 to 6.0
(depending on tissue responsiveness) in the presence of 10µM A23187 and allowed to
relax in RS between contractions. The third contraction (F1) was used to normalize
experimental data by measuring the FP and FT values.
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2.5.2. Permeabilizing with Triton X-100 & “Wake-Up”
RS was replaced with 1% Triton X-100, enough to cover the tissue, for 15
minutes at 30°C. Following permeabilization the tissues were washed thoroughly with
RS to remove the Triton X-100 and held at 30°C.
In order to “wake-up” the artery rings following permeabilization, the tissues
were contracted twice with a free calcium concentration of pCa = 6 and allowed to relax
in RS after each contraction. The second contraction (F1) was used to normalize
experimental data by measuring the FP and FT values.

25
{

Post-permeabilization Wake-up

Grams of Force

α-toxin- normalize to this contraction

Triton X-100 normalize to this contraction

1.0

Solution

Time

relax

calcium

relax

calcium

relax

Warm-up

calcium

60’

approximations

Relaxing Solution
Relaxing Solution + calcium

Figure 7: Post-permeabilization “Wake-Up.” Following permeabilization, the arteries
are contracted with calcium in order to establish a maximal force curve to normalize the
experimental data. The α-toxin “wakes-up” faster and also deteriorate faster; therefore,
two contractions are performed. The Triton X-100 is slower to respond and requires three
wake-up contractions.}
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2.6 Calcium Response Curve- Permeabilized Tissue
To deplete sarcoplasmic reticular calcium, 10µM A23187 (a calcium ionophore)
was used in all permeabilized tissue. In Triton X-100 permeabilized tissue, 1unit/ml of
calmodulin (Sigma Aldrich, St. Louis, MO) was added to compensate for loss during
permeabilization. All tissues and solutions were held at 30°C throughout the calcium
response curve as a change in temperature would alter the calculated free calcium level.
Inhibitors were then added to three of the four chambers and incubated for 15-20
minutes, on average, except when otherwise noted, the fourth chamber acted as the
control. Following incubation, calcium was then added incrementally, allowing for each
contraction to reach a maximal contraction (waiting until the contraction leveled out or
began to drop) before the next dose of calcium was added. Raw data were collected and
normalized before statistics were run.
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2.7 Drugs & Solutions
All detergents, inhibitors and calcium ionophores were purchased from Calbiochem
Corp, San Diego, CA.

2.7.1. Contracting Solution
To activate muscle contractions at specific free calcium levels, “contracting
solutions” (CS) were made by the addition of the appropriate volume of 1M CaCl2
(Fluka Chemicals) stock to the RS bath as determined using WEBMAXC (Patton,
Thompson et al. 2004).

2.7.2. MLCK Inhibitors
Wortmannin was dissolved in dimethylsulfoxide (DMSO) and MLCK Inhibitor
Peptide 18 (MLCK-18) was dissolved in deionized water.

2.7.3. ROK Inhibitors
H-1152, Y-27632 and HA1077 were dissolved in deionized water.

2.7.4. PKC Inhibitors
Bisindolylmaleimide I (GF 109203X) and Gö 6976 were dissolved in DMSO,
Protein Kinase C Inhibitor Peptide 19-31 (PCK 19-31, RFARKGALRQKNV) and
Protein Kinase Cζ Pseudosubstrate inhibitor (PCKζ, SIYRRGARRWRKL) were both
dissolved in 5% acetic acid.
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2.7.5. Calcium Ionophore
A23187, Free Acid, Streptomyces chartreusensis (Calcimycin) was dissolved in
methanol.

2.7.6. α-Adrenergic Receptor Agonist
Phentolamine was dissolved in deionized water (Sigma-Aldrich Co., St. Louis,
MO)

2.8 Statistics
For each study described, the n value was equal to the number of rabbits from
which arteries were taken. Raw data were recorded, normalized, entered into GraphPad
Prism 3.02 (Graphpad Software, Inc., San Diego, CA) and analyzed using the “Sigmoidal
dose-response (variable slope)” equation: Y=Bottom + (Top – Bottom)/
(1+10^((LogEC50-X)*Hillslope)), where X is the logarithm of concentration, Y is the
response, Y starts at the Bottom (minimum) and goes to the Top (maximum) with a
sigmoidal shape. This is identical to the “four parameter logistics equation.” Statistics
were examined on these four parameters: Minimum, Maximum, LogEC50 and Hillslope.
The null hypothesis was examined using Student’s t-test; the null hypothesis was rejected
at P < 0.05. Graphical representations are based on curve-fit data to these four
parameters. Statistical analyses and curve fitting were performed using Prism 3.02, Excel
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2002 (Microsoft Corporation, Redmond, WA) and SigmaPlot 9.01 (Systat Software,
Inc.).

2.8.1. Normalization of Intact Tissue
Experiments conducted in the intact tissues are normalized to the final L0
contraction (F0) because this is the last contraction prior to the manipulation of the tissue.
Therefore, active force is represented as F/F0, where F is the experimental contraction.
These include the standard KCl-induced contraction and calcium concentration-response
curve in the intact tissue.

2.8.2. Normalization of Alpha Toxin Permeabilized Tissue
Experiments conducted in the α-toxin permeabilized artery rings were normalized
to the third “wake-up” contraction following permeabilization. The tissues permeabilized
with α-toxin had variable responses to the first “wake-up”; therefore, three “wake-ups”
were performed where the second and third “wake-up” had to possess the same
responsiveness to the same level of calcium. Experimental data were normalized to the
third “wake-up” (F1) because it is the last contraction prior to the manipulation of the
tissue. Therefore, active force is represented as F2/F1, where F2 is the experimental
contraction. These include all tissues permeabilized with α-toxin.
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2.8.3. Normalization of Triton X-100 Permeabilized Tissue
Experiments conducted in the Triton X-100 permeabilized artery rings were
normalized to the second “wake-up” contraction following permeabilization. The tissues
permeabilized with α-toxin deteriorate more quickly than α-toxin and the first and second
“wake-up” possess the same responsiveness to the same level of calcium. Experimental
data were normalized to the second “wake-up” (F1) because it is the last contraction prior
to the manipulation of the tissue. Therefore, active force is represented as F2/F1, where F2
is the experimental contraction. These include all tissues permeabilized with Triton X100.

2.8.4. Permeabilization Detergents and Curve Fitting
The α-toxin was dissolved in relaxing solution to a concentration of 20µg/ml and
a 10 % Triton X-100 was diluted with relaxing solution to a concentration of 1% Triton
X-100. These solutions were reused and slowly lost potency over 1-2 months time. The
curves shifted to the right and down. A control was used in each experiment and statistics
were run on the experiment versus control for each day. In the graphical representations
beginning with Figure 10, the sigmoidal force curves represented in panel (A) in those
diagrams with multiple panels or in single panel sigmoidal force curves, these sigmoidal
curves are based on a summarized data in order to show the relationship between the
different inhibitors versus a control. The method used to represent these summarized
sigmoidal force curves involved averaging all of the control data for each type of
permeabilization technique. For each individual experiment the difference between
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treatment and control was measured for each tissue; the difference for each type of
inhibitor was then averaged and that difference was plot against the averaged control
curve. This created a summarized curve that represents each inhibitor’s effect compared
to the control. The remaining figures are based on actual data and are manipulated as
described above in the statistics section.

RESULTS

3.1 Intact Tissue- KCl Induced Contraction
There are two phases of a KCl-induced (110mM) contraction in the femoral
artery, an initial peak phase contraction followed by a sustained, tonic phase contraction.
The initial peak phase reaches ~70% of the normalized contraction immediately
following stimulation with a high potassium solution. Following the initial peak, force
continues to develop at a slower rate until it reaches ~90% of the normalized contraction,
at which time the contraction is sustained with only a very small decrease in force over
time. The tonic phase is less than 100% because KCl-induced contractions produced in
the presence of the α-adrenergic receptor antagonist, phentolamine are normalized to that
produced by KCl in the absence of α-receptor blockade, and ~10% of a KCl-induced
contraction without α-receptor blockade can be attributed to release of norephinephrine
from periarterial nerves.
The ROK inhibitors, Y-27632 and HA-1077, selectively inhibited the tonic but
not phasic phase of a KCl-induced contraction (Ratz 2005) in rabbit femoral artery; and
Y-27632 does not inhibit KCl-induced increases in [Ca2+]i, but does inhibit KCl-induced
increases in MLC phosphorylation (Urban, Berg et al. 2003). Moreover, we showed that
1µM of the PKC inhibitor, GF-109203X, did not produce inhibition (Ratz 2005). These
32
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data suggest calcium sensitization occurs during the tonic phase of contraction, and that
ROK but not PKC plays a role in KCl-induced calcium sensitization. Data shown in
Figure 8, in which the newer and highly selective ROK inhibitor, H-1152 was used,
confirms these findings, and a more complete temporal analysis of the effect of GF109203X suggests that PKC may play a minor role in KCl-induced early contraction. In
particular, neither the PKC inhibitor, GF-109203X (1µM) nor the ROK inhibitor, H-1152
(0.3µM) significantly reduced the initial peak contraction. However, the ROK inhibitor
reduced the sustained contraction at both the two and one-half minute and the ten minute
mark, whereas the PKC inhibitor reduced only the two and one-half minute mark. These
data suggest that during a KCl-induced contraction in intact tissue, ROK is largely
responsible for sustained contraction, whereas PKC may play a small role only during the
early phase of the contraction.

Active Force (F/Fo)
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Figure 8. Examples of force tracings (A) and average force responses produced at the
early, peak phase and at 2.5 and 10 min of the tonic phase (B) of contractions induced by
110mM KCl in intact femoral arteries in the absence of a drug (Control) and presence of
GF-109203X (1µM, inhibitor of conventional PKC isotypes) and H-1152 (0.3µM,
inhibitor of ROK). Data in (B) are averages ± SE. n = 3, * = P < 0.05 compared to
control values}
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3.2 Intact Tissue – Calcium Concentration-Response Curve in a KCl-Induced
Contraction
To determine the role of calcium in a KCl-induced (110 mM) steady-state (tonic)
contraction in the intact femoral artery, a calcium concentration-response curve was
constructed using a nominally calcium-free physiological saline solution (0Ca-NPSS).
The tissue did not produce force when treated with the high potassium 0Ca-KPSS
solution alone (data not shown). The calcium concentration-response curve (pCa -4.0 to 2.75) in intact femoral artery incubated in 0Ca-KPSS did not produce an initial peak
contraction. Instead, force developed monotonically to increases in extracellular calcium.
These data support the hypothesis that during membrane depolarization, the level of
extracellular calcium determines the level of [Ca2+]i, and there is a correlation between
the amount of extracellular calcium and the strength of the contraction.
The study shown in Figure 8 was done using a single extracellular calcium
concentration (1.6mM). To determine the degree to which KCl-induced ROK-dependent
tonic contraction is contingent on the level of extracellular calcium, tissues were treated
with the ROK inhibitor, H-1152 (0.3µM), and a calcium concentration-response curve
was constructed and compared to the control response in the absence of the ROK
inhibitor (Figure 9). For a comparison, the effect of the PKC inhibitor, GF-109203X
(1µM) on a calcium concentration-response curve was also studied. A strong MLCK
inhibitor was also used to test the hypothesis that MLCK plays the predominant role in
regulation of KCl and Ca2+-induced contraction. Tissues were treated with kinase
antagonists 15 minutes prior to and during the calcium concentration-response curve. The
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MLCK inhibitor nearly abolished the contraction (P < 0.001), indicating that a KClinduced contraction is highly dependent on MLCK. The ROK inhibitor also significantly
reduced contractions at all levels of the calcium concentration-response curve, (P <
0.001), whereas the PKC inhibitor did not significantly attenuate force at any calcium
concentration. These data support previous studies indicating that during a KCl-induced
contraction, ROK is activated, allowing for calcium sensitization to occur, whereas the
role of conventional PKC isotypes is insignificant.
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Figure 9.KCl-induced calcium concentration-response curve. Force tracing of
contraction induced by increasing levels of calcium (pCa -4.0 to -2.75) in intact femoral
arteries in a 110mM KCl solution in the absence of a drug (Control) and the presence of
GF-109203X (1µM, inhibitor of conventional PKC isotypes), H-1152 (0.3µM, inhibitor
of ROK) and wortmannin (1µM, inhibitor of MLCK). n = 3, * = P < 0.001.
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3.3 Permeabilized Tissue – Alpha Toxin vs. Triton X-100
Two different detergents were used to permeabilize the femoral artery, 20ug/ml
alpha toxin and 1% Triton X-100, and calcium concentration-response curves (pCa -7.5.0
to -5.5) were constructed. The chemically permeabilized tissue produced a maximal
contraction of approximately 8-10% of KCl-induced intact tissue contraction.
Additionally, the α-toxin permeabilized tissue responded to lower doses of calcium and
reached a higher maximum contraction then the Triton X-100 permeabilized tissue
(Figure 10 (A)). The Triton X-100 preparation had a significant decrease in maximal
force (Figure 10 (C)) and EC50 (Figure 10 (B)) compared to the α-toxin preparation (P <
0.05). This shift to the right produced in Triton X-100 permeabilized muscle compared to
α-toxin permeabilized muscle is supported by previous studies (Kitazawa, Takizawa et al.
1999; Adegunloye, Lamarre et al. 2003). However, one study found the opposite to be
true; they found that Triton X-100 had higher calcium sensitivity than α-toxin (Van
Heijst, Blange et al. 2000).
These data support that of others who showed that there is either membrane
bound processes that are being disrupted or the loss of several intracellular molecules
from Triton X-100-permeabilized smooth muscle (Li, Eto et al. 1998; Kitazawa,
Takizawa et al. 1999; Adegunloye, Lamarre et al. 2003), that are involved in calcium
sensitization, that are not disrupted or lost in the α-toxin preparation.
The Hill Slope for the Triton X-100 preparation was higher than the α-toxin
preparation, but it was not significant (Figure 10 (D)). This suggests that the
cooperativity for calcium is similar in the two preparations.
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Figure 10. Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in chemical permeabilized femoral arteries, skinned
with either 20µg/ml α-toxin (retains both SR and receptor coupling, forming pores
permeable to molecules of up to 3kDa) or 1 % Triton X-100 (extensively permeabilized
cell in which all membrane functions are eliminated including the loss of receptor and
Sarcoplasmic Reticulum (SR) coupling) in the absence of any drug inhibitors (Controls),
respectively C-Toxin or C-Triton. Data in (B, C, D) are averages ± SE. α-toxin n = 6,
Triton X-100 n = 14, * = P < 0.05
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3.4 Permeabilized Tissue- MLCK inhibitor
To determine if MLCK plays the predominant role in the regulation of Ca2+induced contractions in chemically permeabilized tissue, a calcium concentrationresponse curve (pCa -7.5.0 to -5.5) was performed in both α-toxin and Triton X-100
permeabilized femoral artery in the presence of MLCK inhibitors. Tissues were treated
with kinase antagonists 20 minutes prior to and during the calcium concentrationresponse curve. Low doses of wortmannin, 1µM, significantly reduced the maximum
peak contraction (Figures 11 (A)(C) & 12 (A)(C)) and the logEC50 (Figures 11 (B) & 12
(B)) in both the α-toxin and Triton X-100 preparations, whereas the Hill slope (Figures
11 (D) & 12 (D)) was not significantly different in either of the two preparations, (P <
0.005). High doses of wortmannin, 10µM, completely abolished the contraction except at
the very highest doses of calcium. These data suggest that a Ca2+-induced contraction in
α-toxin and Triton X-100 chemically permeabilized tissue is highly dependent on MLCK.
Data was normalized and curve-fitted to a sigmoidal curve as described in the
Materials & Methods section. Statistics were run on the 1µM wortmannin preparations,
additional data is needed to run statistics on the 10µM preparations.

3.4.1. Alpha Toxin - 1µM Wortmannin
The minimum (Figures 11 (A)(C)) of the force curve produced by tissues exposed
to 1µM wortmannin (0.002 + 0.002 F2/F1) was not significantly different than that
produced by control tissues (0.005 + 0.004 F2/F1), (P = 0.47).

40
The maximum (Figures 11 (A)(C)) of the force curve was significantly different
when comparing 1µM wortmannin-treated tissue (0.39 + 0.14 F2/F1) and control tissues
(1.04 + 0.07 F2/F1), (P = 0.01).
Higher calcium levels were required to initiate force in 1µM wortmannin-treated
tissues (pCa -6.5) compared to the control tissues (pCa -7.0); resulting in a significant
difference in log (Figure 11 (B)) between the 1µM wortmannin treated tissue (pCa -6.39
+ 0.04) compared to the control (pCa -6.6 + 0.09), (P = 0.005).
The Hill slope (Figure 11 (D)) of the force curve was not significantly different
when comparing 1µM wortmannin treated tissues (8.53 + 3.97) and control tissues (5.98
+ 1.26), (P = 0.57).
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Figure 11. Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in 20µg/ml α-toxin (retains both SR and receptor
coupling, forming pores permeable to molecules of up to 3kDa) permeabilized femoral
arteries, in the absence of a drug (Control) and presence of wortmannin (1µM & 10µM,
inhibitor of MLCK). Data in (B, C, D) are averages ± SE. n = 3, * = P < 0.05 compared
to control values
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3.4.2. Triton X-100- 1µM wortmannin
The minimum (Figure 12 (A)(C)) of the force curve produced by tissues exposed
to 1µM wortmannin (0.001 + 0.002 F2/F1) was not significantly different than that
produced by control tissues (0.001 + 0.001 F2/F1), (P = 0.91).
The maximum (Figure 12 (A)(C)) of the force curve was significantly different
when comparing 1µM wortmannin-treated tissue (0.36 + 0.05 F2/F1) and control tissues
(0.79 + 0.04 F2/F1), (P = 0.0005).
Higher calcium levels were required to initiate force in 1µM wortmannin treated
tissues (pCa -6.25) compared to the control tissues (pCa -6.5); resulting in a significant
difference in logEC50 (Figure 12 (B)) between the 1µM wortmannin-treated tissues (pCa
-6.18 + 0.06) and control tissues (pCa -6.47+ 0.05), (P = 0.01).
The Hill slope (Figure 12 (D)) of the force curve was not significantly different
when comparing 1µM wortmannin treated tissues (7.54 + 1.46) and control tissues (5.44
+ 1.45), (P = 0.35).
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Figure 12. Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in 1% Triton X-100 (extensively permeabilized cell in
which all membrane functions are eliminated including the loss of receptor and
Sarcoplasmic Reticulum (SR) coupling) permeabilized femoral arteries, in the absence of
a drug (Control) and presence of wortmannin (1µM & 10µM, inhibitor of MLCK). Data
in (B, C, D) are averages ± SE. n = 4, * = P < 0.05 compared to control values.
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3.5 Permeabilized Tissue- Specific ROK Inhibitors
To determine the degree to which a Ca2+-induced contraction is contingent on
ROK in chemically permeabilized femoral artery, a calcium concentration-response curve
(pCa -7.5.0 to -5.5) was performed in α-toxin and Triton X-100 permeabilized tissues in
the presence of ROK inhibitors. Tissues were treated with ROK antagonists 15 minutes
prior to and during the calcium concentration-response curve. Three doses, 0.3µM, 1µM
and 3µM, of the specific ROK inhibitor H-1152 were used in both preparations. For a
comparison, additional ROK inhibitors were used in both preparations: 10µM Y-27632
and 10µM HA-1077. Surprisingly, there was only one significant difference in all of
these preparations, the Hill slope of the 3µM H1152 (Figure 16 (C)) in the α-toxin
preparation, but not in the Triton X-100 preparation. These data suggest that a Ca2+induced contraction in α-toxin and Triton X-100 chemically permeabilized tissue is not
dependent on ROK.
Data was normalized and curve-fitted to a sigmoidal curve as described in the
Materials & Methods section. Statistics were run on all of these samples except for the
1µM H-1152, 10µM Y-27632 and 10µM HA-1077 α-toxin preparations.
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3.5.1. Alpha Toxin - 0.3µM H1152
The minimum (Figure 13 (A)(C)) of the force curve produced by tissues exposed
to 0.3µM H1152 (0.005 + 0.004 F2/F1) was not significantly different than that produced
by control tissues (0.01 + 0.012 F2/F1), (P = 0.69).
The maximum (Figure 13 (A)(C )) of the force curve was not significantly
different when comparing 0.3µM H1152-treated tissues (0.96 + 0.10 F2/F1) and control
tissues (1.07 + 0.04 F2/F1), (P = 0.34).
The Log EC50 (Figure 13 (B)) produced by tissues exposed to 0.3µM H1152 (pCa
-6.69 + 0.09) was not significantly different than that produced by control tissues (pCa 6.79 + 0.12), (P = 0.53).
The Hill slope (Figure 13 (C)) of the force curve was not significantly different
when comparing 0.3µM H1152-treated tissue (8.33 + 1.27) and control tissues (5.90 +
1.51), (P = 0.29).
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Figure 13. Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in 20µg/ml α-toxin (retains both SR and receptor
coupling, forming pores permeable to molecules of up to 3kDa) permeabilized femoral
arteries, in the absence of a drug (Control) and presence of H-1152 (0.3µM, 1µM &
10µM, inhibitor of ROK). Data in (B, C, D) are averages ± SE. n = 3.
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3.5.2. Triton X-100 - 0.3µM H1152
The minimum (Figures 14 (A)(C)) of the force curve produced by tissues exposed
to 0.3µM H1152 (-0.002 + 0.0007 F2/F1) was not significantly different than that
produced by control tissues (0.0007 + 0.0009 F2/F1), (P = 0.09).
The maximum (Figures 14 (A)(C)) of the force curve was not significantly
different when comparing 0.3µM H1152-treated tissues (0.82 + 0.05 F2/F1) and control
tissues (0.76 + 0.04 F2/F1), (P = 0.08).
The Log EC50 (Figures 14 (B)) produced by tissues exposed to 0.3µM H1152
(pCa -6.25 + 0.05) was not significantly different than that produced by control tissues
(pCa -6.42 + 0.07), (P = 0.08).
The Hill slope (Figures 14 (D)) of the force curve was not significantly different
when comparing 0.3µM H1152-treated tissue (5.47 + 0.96) and control tissues (6.98 +
1.26), (P = 0.37).

48
1.0

-7.0

A.

LogEC50

-6.8
Control

0.6

-6.6

0.3µM H1152

0.4

pCa

Active Force (F2/F1)

0.8

B.

1µM H1152

0.2

-6.4

3µM H1152

-6.2

0.0
-0.2
-7.5

-7.0

-6.5

-6.0

-5.5

-6.0

Control

0.3 µM
H-1152

Control

0.3 µM
H-1152

pCa

C.

10

Min & Max

0.8

8

0.6

6

Hill Slope

Active Force (F2/F1)

1.0

0.4
0.2
0.0

D.

4
2

Control

0.3 µM
H-1152

0

Figure 14. Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in 1% Triton X-100 (extensively permeabilized cell in
which all membrane functions are eliminated including the loss of receptor and
Sarcoplasmic Reticulum (SR) coupling) permeabilized femoral arteries, in the absence of
a drug (Control) and presence of H-1152 (0.3µM, inhibitor of ROK). Data in (B, C, D)
are averages ± SE. n = 5.
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3.5.3. Triton X-100 - 1µM H1152
The minimum (Figures 15 (A)(C)) of the force curve produced by tissues exposed
to 1µM H1152 (-0.0013 + 0.001 F2/F1) was not significantly different than that produced
by control tissues (0.006 + 0.005 F2/F1), (P = 0.20).
The maximum (Figures 15 (A)(C)) of the force curve was not significantly
different when comparing 1µM H1152-treated tissues (0.75 + 0.03 F2/F1) and control
tissues (0.79 + 0.04 F2/F1), (P = 0.20).
The Log EC50 (Figure 15 (B)) produced by tissues exposed to 1µM H1152 (pCa 6.23 + 0.04 was not significantly different than that produced by control tissues (pCa 6.32 + 0.09), (P = 0.08).
The Hill slope (Figure 15 (D) the force curve produced by tissues exposed to 1µM
H1152 (5.47 + 0.96) and control tissues (6.98 + 1.26), (P = 0.39).
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Figure 15. Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in 1% Triton X-100 (extensively permeabilized cell in
which all membrane functions are eliminated including the loss of receptor and
Sarcoplasmic Reticulum (SR) coupling) permeabilized femoral arteries, in the absence of
a drug (Control) and presence of H-1152 (1µM, inhibitor of ROK). Data in (B, C, D) are
averages ± SE. n = 4.
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3.5.4. Alpha Toxin - 3µM H1152
The minimum (Figures 16 (A)(C)) of the force curve produced by tissues exposed
to 3µM H1152 (0.004 + 0.0008 F2/F1) was not significantly different than that produced
by control tissues (0.01 + 0.005 F2/F1), (P = 0.19).
The maximum (Figures 16 (A)(C) of the force curve was not significantly
different when comparing 3µM H1152-treated tissues (1.31 + 0.23 F2/F1) and control
tissues (1.43 + 0.25 F2/F1), (P = 0.75).
The LogEC50 (Figures 16 (B)) produced by tissues exposed to 3µM H1152 (pCa 6.39 + 0.03) was not significantly different than that produced by control tissues (pCa 6.40 + 0.04), (P = 0.91).
The Hill slope (Figures 16 (D)) the force curve was significantly different when
comparing 3µM H1152-treated tissues (9.11 + 0.14) and control tissues (7.26 + 0.65), (P
= 0.05).
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Figure 16. . Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in 20µg/ml α-toxin (retains both SR and receptor
coupling, forming pores permeable to molecules of up to 3kDa) permeabilized femoral
arteries, in the absence of a drug (Control) and presence of H-1152 (3µM, inhibitor of
ROK). Data in (B, C, D) are averages ± SE. n = 3, * = P < 0.05 compared to control
values.
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3.5.5. Triton X-100 - 3µM H1152
The minimum (Figures 17 (A)(C)) of the force curve produced by tissues exposed
to 3µM H1152 (-0.0005 + 0.002 F2/F1) was not significantly different than that produced
by control tissues (0.001 + 0.001 F2/F1), (P = 0.47).
The maximum (Figures 17 (A)(C)) of the force curve was not significantly
different when comparing 3µM H1152-treated tissues (0.80 + 0.04 F2/F1) and control
tissues (0.78 + 0.04 F2/F1), (P = 0.71).
The LogEC50 (Figure 17 (B)) produced by tissues exposed to 3µM H1152 (pCa 6.24 + 0.04) was not significantly different than that produced by control tissues (pCa 6.29 + 0.09), (P = 0.63).
The Hill slope (Figure 17 (D)) of the force curve was not significantly different
when comparing 3µM H1152-treated tissue (5.94 + 0.52) and control tissues (5.99 +
0.56), (P = 0.94).
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Figure 17. Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in 1% Triton X-100 (extensively permeabilized cell in
which all membrane functions are eliminated including the loss of receptor and
Sarcoplasmic Reticulum (SR) coupling) permeabilized femoral arteries, in the absence of
a drug (Control) and presence of H-1152 (3µM, inhibitor of ROK). Data in (B, C, D) are
averages ± SE. n = 4.
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3.5.6. Alpha Toxin - 10µM Y27632 & 10µM HA1077
Our protocol requires that a minimum of an n = 3 are run, in order to perform
statistical analysis. However, these two ROK inhibitors, 10µM Y-27632 and 10µM HA1077, exhibited the same characteristics as our previous ROK studies, as there was no
inhibition.. Therefore, additional experiments were not performed with these inhibitors as
it suggested that additional ROK inhibitor studies would yield similar results.
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Figure 18. . Examples of force tracing in 20µg/ml α-toxin (retains both SR and receptor
coupling, forming pores permeable to molecules of up to 3kDa) permeabilized femoral
arteries, in the absence of a drug (Control) and presence of 10µM Y-27632 and 10µM
HA-1077 (both are inhibitors of ROK). n = 2.
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3.5.7. Triton X-100 - 10µM Y27632
The minimum (Figures 19 (A)(C)) of the force curve produced by tissues exposed
to 10µM Y27632 (0.002 + 0.005 F2/F1) was not significantly different than that produced
by control tissues (0.004 + 0.006 F2/F1), (P = 0.8).
The maximum (Figures 19 (A)(C)) of the force curve was not significantly
different when comparing 10µM Y27632-treated tissue (0.73 + 0.03 F2/F1) and control
tissues (0.77 + 0.06 F2/F1), (P = 0.58).
The LogEC50 (Figure 19 (B)) produced by tissues exposed to 10µM Y27632 (pCa
-6.25 + 0.03) was not significantly different than that produced by control tissues (pCa 6.28 + 0.04), (P = 0.56).
The Hill slope (Figure 19 (D)) of the force curve was not significantly different
when comparing 10µM Y27632-treated tissue (8.67 + 2.87) and control tissues (7.46 +
1.94), (P = 0.74).
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Figure 19. Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in 1% Triton X-100 (extensively permeabilized cell in
which all membrane functions are eliminated including the loss of receptor and
Sarcoplasmic Reticulum (SR) coupling) permeabilized femoral arteries, in the absence of
a drug (Control) and presence of Y-27632 (10µM, inhibitor of ROK). Data in (B, C, D)
are averages ± SE. n = 3.
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3.5.8. Triton X-100 - 10µM HA1077
The minimum (Figures 20 (A)(C)) of the force curve produced by tissues exposed
to 10µM HA1077 (0.002 + 0.004 F2/F1) was not significantly different than that produced
by control tissues (0.004 + 0.006 F2/F1), (P = 0.81).
The maximum (Figures 20 (A)(C)) of the force curve was not significantly
different when comparing 10µM HA1077-treated tissues (0.76 + 0.04 F2/F1) and control
tissues (0.77 + 0.06 F2/F1), (P = 0.94).
The LogEC50 (Figure 20 (B)) produced by tissues exposed to 10µM HA1077
(pCa -6.26 + 0.03 was not significantly different than that produced by control tissues
(pCa -6.28 + 0.04), (P = 0.82).
The Hill slope (Figure 20 (D)) of the force curve was not significantly different
when comparing 10µM HA1077-treated tissues (7.68 + 2.28) and control tissues (7.46 +
1.94), (P = 0.94).
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Figure 20. Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in 1% Triton X-100 (extensively permeabilized cell in
which all membrane functions are eliminated including the loss of receptor and
Sarcoplasmic Reticulum (SR) coupling) permeabilized femoral arteries, in the absence of
a drug (Control) and presence of HA-1077 (10µM, inhibitor of ROK). Data in (B, C, D)
are averages ± SE. n = 3.
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3.6 Permeabilized Tissue- PKC inhibitors
To determine the degree to which a Ca2+-induced contraction is contingent on
PKC in chemically permeabilized femoral artery, a calcium concentration-response curve
(pCa -7.5.0 to -5.5) was performed in α-toxin and Triton X-100 permeabilized tissue in
the presence of PKC inhibitors. Tissues were treated with PKC antagonists for 15-45
minutes prior to and during the calcium concentration-response curve. Two doses, 1 µM
and 3 µM, of the PKC inhibitor GF 109203X were used in the α-toxin preparation, and
three doses, 1 µM, 3 µM and 3 µM, were used in the Triton X-100 preparation. For a
comparison, additional PKC inhibitors were used in the α-toxin preparation 1 µM Gö
6976 (n = 1), 10 µM (n = 1) and 20 µM (n = 1) PKC 19-31 (a pseudosubstrate peptide
inhibitor of PKCα), and 10 µM pseudosubstrate peptide inhibitor of PKCζ (n = 2).
Statistics were not run on these data, instead it provided a dosage guideline for the Triton
X-100 preparations. In the Triton X-100 preparations the following PKC inhibitors were
used, 20µM PKC 19-31 (n = 3) and 10µM pseudosubstrate peptide inhibitor of PKCζ (n
= 3). The different antagonists and dosages of antagonist targeted different PKC isotypes.
As a result, these inhibitors produced varied results.
Data were normalized and curve-fitted to a sigmoidal curve as described in the
Materials & Methods section.
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3.6.1. Alpha Toxin - 1µM GF 109203X
The minimum (Figures 21 (A)(C)) of the force curve produced by tissues exposed
to 1µM GF 109203X (-0.12 + 0.02 F2/F1) was not significantly different than that
produced by control tissues (0.01 + 0.02 F2/F1), (P = 0.23).
The maximum (Figures 21 (A)(C)) of the force curve was significantly different
when comparing 1µM GF 109203X-treated tissues (0.69 + 0.06 F2/F1) and control tissues
(1.08 + 0.04 F2/F1), (P = 0.01).
The LogEC50 (Figure 21 (B)) produced by tissues exposed to 1µM GF 109203X
(pCa -6.76 + 0.13) was not significantly different than that produced by control tissues
(pCa -6.79 + 0.12), (P = 0.86).
The Hill slope (Figure 21 (D)) of the force curve was not significantly different
when comparing 1µM GF 109203X- treated tissue (3.50 + 1.01) and control tissues (5.90
+ 1.51), (P = 0.26).

3.6.2. Alpha Toxin - 3µM GF 109203X
The minimum (Figures 21 (A)(C)) of the force curve produced by tissues exposed
to 3µM GF 109203X (0.0003 + 0.005 F2/F1) was not significantly different than that
produced by control tissues (0.01 + 0.005 F2/F1), (P = 0.17).
The maximum (Figures 21 (A)(C)) of the force curve was not significantly
different when comparing 3µM GF 109203X-treated tissues (0.70 + 0.13 F2/F1) and
control tissues (1.43 + 0.25 F2/F1), (P = 0.06).
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The LogEC50 (Figure 21 (B)) produced by tissues exposed to 3µM GF 109203X
(pCa -6.23 + 0.05) was not significantly different than that produced by control tissues
(pCa -6.40 + 0.04), (P = 0.052).
The Hill slope (Figure 21 (D)) of the force curve was significantly different when
comparing 3µM GF 109203X-treated tissue (3.31 + 0.51) and control tissues (7.25 +
0.65), (P = 0.01).
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Figure 21. Examples of force tracing (A) LogEC50 (B1 & B2), minimum and maximal
contractions (C1 & C2) and Hillslope (D1 & D2) in 20µg/ml α-toxin (retains both SR and
receptor coupling, forming pores permeable to molecules of up to 3kDa) permeabilized
femoral arteries, in the absence of a drug (Control) and presence of GF-109203X (1µM, a
potent inhibitor of conventional PKC isotypes; 3µM, inhibitor of atypical PKC isotypes).
Data in (B1, B2, C1, C2, D1, D2) are averages ± SE. n = 3, * = P < 0.05 compared to
control values.
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3.6.3. Triton X-100- 1µM GF 109203X
The minimum (Figures 22 (A)(C)) of the force curve produced by tissues exposed
to 1µM GF 109203X (-0.002 + 0.0007 F2/F1) was not significantly different than that
produced by control tissues (0.0004 + 0.0009 F2/F1), (P = 0.07).
The maximum (Figures 22 (A)(C)) of the force curve was not significantly
different when comparing 1µM GF 109203X-treated tissues (0.76 + 0.06 F2/F1) and
control tissues (0.74 + 0.04 F2/F1), (P = 0.77).
The LogEC50 (Figure 22 (B)) produced by tissues exposed to 1µM GF 109203X
(pCa -6.29 + 0.04) was not significantly different than that produced by control tissues
(pCa -6.37 + 0.05), (P = 0.27).
The Hill slope (Figure 22 (D)) of the force curve was not significantly different
when comparing 1µM GF 109203X treated tissues (6.64 + 0.95) and control tissues (7.36
+ 1.16), (P = 0.64).

3.6.4. Triton X-100- 3µM GF 109203X
The minimum (Figures 22 (A)(C)) of the force curve produced by tissues exposed
to 3µM GF 109203X (-0.002 + 0.0005 F2/F1) was not significantly different than that
produced by control tissues (0.008 + 0.007 F2/F1), (P = 0.21).
The maximum (Figures 22 (A)(C)) of the force curve was not significantly
different when comparing 3µM GF 109203X-treated tissues (0.68 + 0.05 F2/F1) and
control tissues (0.78 + 0.04 F2/F1), (P = 0.18).
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The LogEC50 (Figure 22 (B)) produced by tissues exposed to 3µM GF 109203X
(pCa -6.27 + 0.02) was not significantly different than that produced by control tissues
(pCa -6.27 + 0.02), (P = 0.10).
The Hill slope (Figure 22 (D)) of the force curve was significantly different when
comparing 3µM GF 109203X treated tissues (4.72 + 0.17) and control tissues (5.30 +
0.10), (P = 0.04).

3.6.5. Triton X-100- 10µM GF 109203X
The minimum (Figures 22 (A)(C)) of the force curve produced by tissues exposed
to 10µM GF 109203X (0.002 + 0.003 F2/F1) was not significantly different than that
produced by control tissues (0.007 + 0.005 F2/F1), (P = 0.50).
The maximum (Figures 22 (A)(C)) of the force curve was significantly different
when comparing 10µM GF 109203X-treated tissues (0.51 + 0.08 F2/F1) and control
tissues (0.76 + 0.05 F2/F1), (P = 0.03).
The LogEC50 (Figure 22(B)) produced by tissues exposed to 10µM GF 109203X
(pCa -6.21 + 0.07) was not significantly different than that produced by control tissues
pCa -6.25 + 0.02), (P = 0.59).
The Hill slope (Figure 22 (D)) of the force curve was not significantly different
when comparing 10µM GF 109203X treated tissues (6.18 + 2.29) and control (6.17 +
1.23), (P = 1.00).
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Figure 22. Examples of force tracing (A) LogEC50 (B1, B2, B3), minimum and maximal
contractions (C1, C2, C3) and Hillslope (D1, D2, D3) in 1% Triton X-100 (extensively
permeabilized cell in which all membrane functions are eliminated including the loss of
receptor and Sarcoplasmic Reticulum (SR) coupling) permeabilized femoral arteries, in
the absence of a drug (Control) and presence of GF-109203X (1µM, a potent inhibitor of
conventional PKC isotypes; 3µM & 10µM, inhibitor of atypical PKC isotypes). Data in
(B1, B2, B3, C1, C2,C3, D1, D2, D3) are averages ± SE. n = 5,3,5- respectively, * = P <
0.05 compared to control values.
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3.6.6. Alpha Toxin - 0.1µM Gö 6976
Our protocol requires that a minimum of an n = 3 are run, in order to perform
statistical analysis. However, appears that this antagonist of conventional PKC isotypes
does have an inhibitory effect on the α-toxin permeabilized tissue. This is consistent with
the previous data in which 1 and 3µM GF-109203X causes inhibition.
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Figure 23. Examples of force tracing in 20µg/ml α-toxin (retains both SR and receptor
coupling, forming pores permeable to molecules of up to 3kDa) permeabilized femoral
arteries, in the absence of a drug (Control) and presence of 0.1µM Gö-6976 (inhibitor of
conventional PKC isotypes). n = 1.
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3.6.7. Alpha Toxin - 10µM PKC 19-31, 20µM PKC 19-31, 10µM PKCζ
Statistics were not run on these compounds. However, it appears that there is
variation in the pseudosubstrate PKC inhibitor (PKC 19-31) that affects is reported to
inhibit conventional PKC isotypes, based on dosage. The atypical pseudosubstrate
peptide inhibitor of PKCζ appeared to have induced calcium sensitization.
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Figure 24. Examples of force tracing in 20µg/ml α-toxin (retains both SR and receptor
coupling, forming pores permeable to molecules of up to 3kDa) permeabilized femoral
arteries, in the absence of a drug (Control) and presence of PKC 19-31 (10µM & 20µM,
pseudosubstrate PKC conventional isotype inhibitor) and PKCζ inhibitor (atypical
pseudosubstrate peptide inhibitor). n = 1, 1, 2, respectively.
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3.6.8. Triton X-100- 20µM PKC 19-31
The minimum (Figures 25 (A)(C)) of the force curve produced by tissues exposed
to 20µM PKC 19-31 (0.003 + 0.005 F2/F1) was not significantly different than that
produced by control tissues (0.001 + 0.002 F2/F1), (P = 0.79).
The maximum (Figures 25 (A)(C)) of the force curve was not significantly
different when comparing 20µM PKC 19-31-treated tissues (0.64 + 0.06 F2/F1) and
control tissues (0.67 + 0.02 F2/F1), (P = 0.65).
The LogEC50 (Figure 25 (B)) produced by tissues exposed to 20µM PKC 19-31
(pCa -6.39 + 0.03) was significantly different than that produced by control tissues (pCa 6.27 + 0.03), (P = 0.047).
The Hill slope (Figure 25 (D)) of the force curve was not significantly different
when comparing 20µM PKC 19-31-treated tissues (4.54 + 0.78) and control tissues (3.87
+ 0.74), (P = 0.57).
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Figure 25. Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in 1% Triton X-100 (extensively permeabilized cell in
which all membrane functions are eliminated including the loss of receptor and
Sarcoplasmic Reticulum (SR) coupling) permeabilized femoral arteries, in the absence of
a drug (Control) and presence of PKC 19-31 (20µM, pseudosubstrate PKC conventional
isotype inhibitor). Data in (B, C, D) are averages ± SE. n = 3, * = P < 0.05 compared to
control values.
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3.6.9. Triton X-100- 10µM PKCζ
The minimum (Figures 26 (A)(C)) of the force curve produced by tissues
exposed to 10µM pseudosubstrate PKC atypical isotype inhibitor-PKCζ (0.006 + 0.005
F2/F1) was not significantly different than that produced by control tissues (0.001 + 0.002
F2/F1), (P = 0.43).
The maximum (Figures 26 (A)(C)) of the force curve was not significantly
different when comparing 10µM pseudosubstrate PKC atypical isotype inhibitor-PKCζtreated tissues (0.69 + 0.05 F2/F1) and control tissues (0.67 + 0.02 F2/F1), (P = 0.68).
The LogEC50 (Figure 26 (B)) produced by tissues exposed to 10µM
pseudosubstrate PKC atypical isotype inhibitor-PKCζ (pCa -6.27 + 0.03) was not
significantly different than that produced by control tissues (pCa -6.33 + 0.03), (P =
0.14).
The Hill slope (Figure 26 (D)) of the force curve was not significantly different
when comparing 10µM pseudosubstrate PKC atypical isotype inhibitor-PKCζ treated
tissue (3.87 + 0.74) and control tissues (4.17 + 0.64), (P = 0.77).
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Figure 26. Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in 1% Triton X-100 (extensively permeabilized cell in
which all membrane functions are eliminated including the loss of receptor and
Sarcoplasmic Reticulum (SR) coupling) permeabilized femoral arteries, in the absence of
a drug (Control) and presence of pseudosubstrate PKC atypical isotype inhibitor-PKCζ
(10µM). Data in (B, C, D) are averages ± SE. n = 3.
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4.1 Additional Peptide MLCK Inhibitor
We previously established that MLCK was the main kinase responsible for
contraction in both the α-toxin and Triton X-100 chemically permeabilized femoral
arterial smooth muscles. We also found that the peptide PKC inhibitors were not
behaving as expected. To establish a baseline for peptide inhibitors, we added a peptide
inhibitor of MLCK, MLCK-18. We did not get the strong inhibition we saw with the
wortmannin preparations.

4.1.1. Alpha Toxin - 1µM & 10µM MLCK-18
Our protocol requires that a minimum of an n = 3 are run, in order to perform
statistical analysis. However, appears that there is variation in the MLCK inhibitor
(MLCK-18) based on dosage.
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Figure 27. Examples of force tracing in 20µg/ml α-toxin (retains both SR and receptor
coupling, forming pores permeable to molecules of up to 3kDa) permeabilized femoral
arteries, in the absence of a drug (Control) and presence of MLCK-18 (1µM & 10µM,
peptide inhibitor of MLCK). n = 1.
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4.1.2. Triton X-100- 10µM MLCK-18
The minimum (Figures 28 (A)(C)) of the force curve produced by tissues
exposed to 10µM MLCK-18 (0.008 + 0.008 F2/F1) was not significantly different
than that produced by control tissues (0.001 + 0.002 F2/F1), (P = 0.49).
The maximum (Figures 28 (A)(C)) of the force curve was significantly
different when comparing 10µM MLCK-18-treated tissue (0.53 + 0.005 F2/F1)
and control tissues (0.67 + 0.03 F2/F1), (P = 0.003).
The LogEC50 (Figure 28 (B)) produced by tissues exposed to 10µM
MLCK-18 (pCa -6.46 + 0.03) was significantly different than that produced by
control tissues (pCa -6.27 + 0.03), (P = 0.012).
The Hill slope (Figure 28 (D)) of the force curve was not significantly
different when comparing 10µM MLCK-18-treated tissues (3.87 + 0.26) and
control tissues (3.87 + 0.74), (P = 0.57).
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Figure 28. Examples of force tracing (A) LogEC50 (B), minimum and maximal
contractions (C) and Hillslope (D) in 1% Triton X-100 (extensively permeabilized cell in
which all membrane functions are eliminated including the loss of receptor and
Sarcoplasmic Reticulum (SR) coupling) permeabilized femoral arteries in the absence of
a drug (Control) and presence of 10µM MLCK-18, (peptide inhibitor of MLCK). Data in
(B, C, D) are averages ± SE. n = 3, * = P < 0.05 compared to control values.
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DISCUSSION

KCl-induced contraction has proven to be a valuable tool in the study of smooth
muscle regulation (Ratz 2005), as it bypasses GPCR stimulation and activates smooth
muscle by changing the K+ equilibrium potential and clamping membrane potential at
some value above the resting level (Bolton 1979). The depolarization of the membrane
activates voltage activated calcium channels (VOCCS) and allows for an influx of
calcium, increasing [Ca2+]i, resulting in smooth muscle cell contraction. It also has been
observed that membrane depolarization by KCl can cause Ca2+ -sensitization
(Yanagisawa and Okada 1994; Ratz 2005). The proposal that Ca2+ -sensitization is caused
primarily by inhibition of MLC phosphatase activity has gained widespread support (see
(Somlyo and Somlyo 2003) for a review and for review on MLC phosphatase, see
(Hartshorne, Ito et al. 1998; Hartshorne, Ito et al. 2004; Ratz 2005) for a review see Ratz
2005). The general model is that GPCR stimulation reduced MLC phosphatase activity
by phosphorylation of the MLC phosphatase regulatory subunit MYPT1 and the 17-kDa
PKC-activated phosphatase inhibitor CPI-17 (Fujihara, Walker et al. 1997; Hartshorne,
Ito et al. 1998; Feng, Ito et al. 1999; Eto 2001; Eto, Kitazawa et al. 2004, for review see
(Ratz 2005)). However, whether an increase in [Ca2+]i, due to the activation of VOCCS,
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2+

or membrane depolarization itself plays the principle role in KCl-induced Ca sensitization remains to be determined (Ratz 2005). Several studies using Y-27632, a
selective ROK inhibitor, have provided evidence of a decrease in force, without
inhibition of KCl-induced increases in [Ca2+]i; suggesting that a KCl-induced contraction
increases Ca2+-sensitivity by the activation of ROK (review in (Ratz 2005)). Therefore,
the purpose of this study was to test the hypothesis that KCl-induced Ca2+-sensitization is
a result of Ca2+-induced activation of ROK.
In order to test this hypothesis, we first wanted to determine that ROK, and not
PKC, is primarily responsible for the tonic phase of a KCl-induced contraction in intact
rabbit femoral artery. This was accomplished by treating tissues with either a ROK or
PKC inhibitor before and during a KCl-induced contraction and measuring force over
time. We showed (see Figure 8) that neither the conventional PKC isotype inhibitor, 1µM
GF-109203X, nor the specific ROK inhibitor, 0.3µM H-1152, significantly reduced the
initial peak contraction. However, both inhibitors significantly reduced the earliest
portion of the sustained contraction (2 ½ minutes), whereas the ROK inhibitor only (not
the PKC inhibitor) significantly reduced the later tonic portion of the sustained
contraction (10 minutes). This confirms previous studies in which two other ROK
inhibitors, Y-27632 (Mita, Yanagihara et al. 2002; Urban, Berg et al. 2003; Ratz 2005)
and HA-1077 (Takizawa, Hori et al. 1993), selectively inhibited tonic KCl-induced
contraction (Ratz 2005). These data suggest that during a KCl-induced contraction in the
intact rabbit femoral artery, ROK is largely responsible for the sustained contraction,
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whereas the conventional PKC isotypes may play a small role, but only during the early
phase of the tonic contraction.
We then wanted to determine the degree that the KCl-induced ROK-dependent
tonic contraction was contingent on the level of extracellular calcium. To accomplish
this, a high potassium calcium contraction-response curve (pCa -4.0 to -2.75) was
constructed in intact rabbit femoral artery and compared to tissues treated with a specific
ROK inhibitor, 0.3µM H-1152, under the same conditions. As expected, the ROK
inhibitor significantly reduced the contraction at all levels of the calcium concentrationresponse curve (see Figure 9). We also found that the presence of high potassium alone
was not sufficient to elicit a contraction in the absence of calcium, in the both the control
tissue (the absence of ROK inhibitor) and H-1152 treated tissues. These data suggest that
ROK plays a large role in KCl-induced Ca2+-sensitization, and that calcium is necessary
for a KCl-induced contraction.
Additionally, we found that that there was no initial peak contraction, and that
force developed monotonically to increases in extracellular calcium. Thus, suggesting
that the initial peak found in a “standard” KCl-induced contraction (1.6mM Ca2+) is
dependent on a high initial influx of calcium; and supporting the hypothesis that during
membrane depolarization, the level of extracellular calcium determines the level of
[Ca2+]i, and there is a correlation between the amount of extracellular calcium and the
strength of the contraction.
For a comparison, the experiment was repeated with a conventional PKC isotype
inhibitor, 1µM GF-109203X, and a strong MLCK inhibitor, 1µM wortmannin, to
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determine if the high potassium calcium concentration-response curve altered the
response seen in the “standard” KCl-induced contraction. The PKC inhibitor did not
significantly attenuate force at any calcium concentration, whereas the MLCK inhibitor
nearly abolished the contraction at all calcium concentrations. These data provide
additional evidence that a KCl-induced contraction, ROK and not PKC is primarily
responsible for Ca2+-sensitization; and that a KCl-induced contraction is highly
dependent on MLCK, ruling out the activation of other kinases.
As previously stated, the purpose of this study was to test the hypothesis that KClinduced Ca2+-sensitization is a result of Ca2+-induced activation of ROK. Now that we
established that this is possible, we needed to further explore the relationship between
[Ca2+]i and ROK activation. In order to accomplish this, a methodology was employed
permitting precise control of the amount of [Ca2+]i in the cell during a contraction. To
accomplish this, we “clamped” calcium by chemically permeabilizing isolated rabbit
femoral artery rings and exposing them to solutions containing the desired amounts of
free calcium as determined using WEBMAXC (Patton, Thompson et al. 2004). We
modeled our permeabilization techniques after those described in Kitazawa’s publications
(Kitazawa, Kobayashi et al. 1989; Kobayashi, Kitazawa et al. 1989; Kitazawa, Gaylinn et
al. 1991; Kitazawa, Masuo et al. 1991; Kitazawa, Takizawa et al. 1999; Kitazawa 2004).
Two different permeabilization detergents were used, α-toxin, which forms pore
sizes allowing molecules smaller than 3kDa to pass, such as ATP and EGTA, but not
calmodulin and retains receptor and SR coupling; and Triton X-100, which leads to
extensive permeabilization in which all membrane functions are eliminated, including
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receptor and SR coupling. A calcium concentration-response curve (pCa -7.5 to -5.5) was
constructed in each type of preparation and statistics were run to compare the two. We
found that the α-toxin permeabilized tissue responded to lower dose of calcium and that
both maximal force and LogEC50 were significantly reduced less in the Triton X-100
permeabilized tissues. These data support that of others, showing that there is either
membrane bound processes that are being disrupted or there is a loss of several
intracellular molecules in the Triton X-100 preparation (Li, Eto et al. 1998; Kitazawa,
Takizawa et al. 1999; Adegunloye, Lamarre et al. 2003). We also found that the Hill
slope was not significantly different between these two preparations, meaning the
cooperativity for calcium is similar.
Before testing the ROK inhibitors, we wanted to first ensure that MLCK was the
primary kinase responsible for contraction in the permeabilized artery ring as it is in the
intact KCl-induced contraction. To test this, a calcium concentration-response curve (pCa
-7.5 to -5.5) was performed in the presence of a strong MLCK inhibitor, 1µM
wortmannin, in both permeabilized tissue preparations. As expected, the peak contraction
and LogEC50 were significantly reduced, but not the Hill Slope, in both preparations.
Thus, suggesting that in α-toxin and Triton X-100 permeabilized tissue, MLCK is the
primary kinase responsible for force development; and that the cooperativity of calcium
is not altered by the MLCK inhibitors.
Armed with this knowledge, we then proceeded to test the relationship between
[Ca2+]i and ROK activation by conducting a calcium concentration-response curve (pCa 7.5 to -5.5) in the presence of a specific ROK inhibitor, 0.3µM H-1152, in both the
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permeabilized artery preparations. We showed to our surprise that H-1152 did not cause a
significant inhibition of contraction in either preparation. We repeated the experiments
with higher doses of H-1152 (3µM and 10µM). Again, we did not find any significant
difference in peak contraction or LogEC50. However, there was one significant difference
in the Hill slope out of all of these H-1152 treated tissues, and that was in the 3µM H1152 treated α-toxin preparation, but not in the Triton X-100. For a comparison, the
experiments were repeated with other known ROK inhibitors, 10µM HA-1077 and 10µM
Y-27632, first in the Triton X-100 tissue and then in the α-toxin tissue. These additional
ROK antagonists yielded the same results in the Triton X-100 tissue as did the H-1152
compound; there were no significant differences. The first two experiments in the α-toxin
preparations, also failed to produce any decline in force. Because these data appeared to
simply confirm our findings, we did not pursue additional “n” values. As a result,
because of the low “n” values, statistics were not run on the α-toxin preparation treated
with HA-1077 and Y-27632. These data suggest that in α-toxin and Triton X-100
permeabilized rabbit artery rings either [Ca2+]i alone does not directly activate ROK or
the permeabilization technique itself disrupts the normal ROK signaling system.
As a comparison, we repeated these experiments in the presence of PKC
inhibitors, to see if [Ca2+]i activates other Ca2+-sensitization pathways in tissues
permeabilized by these two methods. We used three different concentrations of GF
109203X, 1µM, 3µM and 10µM, where at 1µM, GF 109203X is a potent inhibitor of
conventional PKC isotypes (α, β, γ) and at 3µM & 10µM, GF 109203X is an inhibitor of
atypical PKC isotypes (ζ, ι, λ). We also used 0.1µM Gö 6976, a selective inhibitor of the
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Ca -dependent PKCα-isozyme: 10µM and 20µM PKC 19-31, a pseudosubstrate peptide
2+

inhibitor of PKCα, and 10µM pseudosubstrate peptide inhibitor of PKCζ. We showed
that the low dose of GF 109203X (3µM) significantly reduced the maximum contraction
in the α-toxin preparation, but not in the Triton X-100 preparation. These findings were
further supported by a single experiment using 0.1µM Gö 6976, a selective inhibitor of
PKCα, in the α-toxin preparation, showing that the maximal contraction was reduced (Gö
6976 was not tested in the Triton X-100 preparation). In the higher doses of GF
109203X, we found that 3µM significantly reduced the Hill slope in both the α-toxin and
Triton X-100 permeabilized tissue preparations, but did not reduce the peak contraction
or the LogEC50; at 10µM we found that the peak contraction was significantly reduced in
the Triton X-100 preparation (10µM GF 109203X was not tested in the α-toxin
preparation). The conventional pseudosubstrate PKC inhibitor, PKC 19-31, had variable
effects in the α-toxin preparation; at 10µM, the maximum was reduced, but a 20µM the
maximum was increased. In the Triton X-100 preparation, 20µM PKC 19-31 increased
the LogEC50. The pseudosubstrate peptide inhibitor of PKCζ (10µM ) had no effect in the
Triton X-100 preparation.
In summary, the conventional PKC isotype inhibitors, 1µM GF 109203X, 10µM
PKC 19-31 and 0.1µM Gö 6976 all appeared to reduce the maximal contraction in the
alpha toxin preparation; whereas 1µM GF 109203X and 10µM PKC 19-31 did not reduce
the maximal contraction in the Triton X-100 preparation, Gö 6976 was not tested in the
Triton X-100 preparation. Our findings support others who have shown that the levels of
many molecules such as PKCα are significantly reduced in smooth muscle tissues
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permeabilized by Triton X-100, but not in tissues permeabilized by α-toxin (Kitazawa,
Takizawa et al. 1999). These data suggest that the PKC α-isozyme is activated in α-toxin
permeabilized rabbit femoral artery ring, therefore, either the permeabilization technique
or the contracting solution, is activating PKCα-induced Ca2+-sensitization.
The atypical PKC isotype inhibitors provided various results. In both the α-toxin
and Triton X-100 preparations, 3µM of GF 109203X significantly reduced the Hill slope.
These data suggests that the cooperativity for calcium is altered. The highest dose of GF
109203X, 10µM, significantly reduced the peak contraction in the Triton X-100
preparation, and although statistics were not performed, it also reduced the maximum
contraction in the α-toxin preparation. Finally, the pseudosubstrate peptide inhibitor of
PKCζ (10µM ) had no effect in the Triton X-100 preparation. These data present
conflicting evidence of the role of PKCζ, in permeabilized rabbit femoral artery;
presenting the possibility that that the permeabilization technique itself is activating
proteases that degrade the peptides before they could exert their effect.
Finally, we wanted to look at another peptide inhibitor to try to determine if the
peptide PKC inhibitors were giving variable results because they were peptides. We had
already established that MLCK was the primary kinase responsible for contraction the αtoxin and Triton X-100 permeabilized rabbit femoral artery. Therefore, we used a peptide
MLCK kinase inhibitor, 10µM MLCK-18. We wanted to establish a control for a peptide
inhibitors, PKC 19-31 and the pseudosubstrate peptide inhibitor of PKCζ, since this was
the first time we used a peptide inhibitor in permeabilized tissue. We found that at low
doses, 1µM, reduced the contraction force, whereas higher doses, 10µM, increased the
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contraction in the α-toxin preparation. In the Triton X-100 preparation, the peak
contraction was significantly reduced, but the LogEC50 was significantly increased using
10µM MLCK-18. These data suggest that the permeabilization techniques themselves
may be activating proteases that are not normally active in intact rabbit femoral artery.
In conclusion, in both the α-toxin and Triton X-100 chemically permeabilized
rabbit femoral artery rings either [Ca2+]i alone does not directly activate ROK or the
permeabilization technique itself disrupts the normal ROK signaling system. Additional
investigations are needed to determine which of these scenarios is the most accurate.
Proteomics and confocal studies would elucidate the extent of the loss of molecules
involved in the ROK pathway as well as the extent of membrane, including caveolar,
disruption caused by these two permeabilization techniques.

CONCLUSIONS
1. During a KCl-induced contraction in the intact rabbit femoral artery, ROK is largely
responsible for the sustained contraction, whereas the conventional PKC isotypes
may play a small role, but only during the early phase of the tonic contraction.

2. ROK plays a large role in KCl-induced Ca2+-sensitization, and that calcium is
necessary for a KCl-induced contraction.

86
2+

3. The initial peak found in a “standard” KCl-induced contraction (1.6mM Ca ) is
dependent on a high initial influx of calcium.

4. During membrane depolarization, the level of extracellular calcium determines the
level of [Ca2+]i, and there is a correlation between the amount of extracellular calcium
and the strength of the contraction.

5. KCl-induced contraction is highly dependent on MLCK, ruling out the activation of
other kinases.

6. The Triton X-100 preparation disrupts more membrane process and/or losses more
intracellular molecules compared to the α-toxin preparation, but the cooperativity of
calcium is similar between the two preparations.

7. In both the α-toxin and Triton X-100 chemically permeabilized rabbit femoral artery,
MLCK is the primary kinase responsible for force development; and that the
cooperativity of calcium is not altered by the MLCK inhibitors.

8. In both the α-toxin and Triton X-100 chemically permeabilized rabbit femoral artery
rings either [Ca2+]i alone does not directly activate ROK or the permeabilization
technique itself disrupts the normal ROK signaling system.
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9.

In α-toxin chemically permeabilized rabbit femoral artery rings conventional PKC
isotypes are activated either by the permeabilization technique or relaxing solution.

10. PKCα is significantly reduced in rabbit femoral artery rings permeabilized by Triton
X-100, but not in tissues permeabilized by α-toxin.

11. There is a possibility that in both α-toxin and Triton X-100 chemical
permeabilization techniques active proteases not normally activated in intact rabbit
femoral artery rings.

FUTURE EXPERIMENTS
1. Use confocal microscopy to look at the different skinned tissue to determine the
extent of caveolae and other membrane disruptions. This may account for the
inability to induced ROK inhibition in the permeabilized cells.

2. Western Blotting to determine what proteins are being lost during the different
skinning preparations. Specifically, look at PKC and ROK as well as their second
messengers and compare these values to an intact tissue.

3. Repeat experiments with the addition of GPCR agonists ROK in both the chemically
permeabilized tissues preparations to determine if these pathways are intact and can
still be activated via GPCRs.
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a. If force does not change in the presence of ROK GPRC agonists it would
support the hypothesis that the mechanisms involved in ROK activation
are disrupted or lost by permeabilization.
b. If force increases in presence of ROK GPRC agonists it would support the
hypothesis that [Ca2+]i alone does not activate ROK.

4. Repeat experiments with the addition of GPCR agonists PKC in both the chemically
permeabilized tissues preparations to determine if these pathways are intact and can
still be activated via GPCRs.

5. Repeat the protein inhibitor experiments in the presence of protease inhibitors.

6. Analyze the detergent solutions to determine if the falling tone is due to a reduced
effectiveness to permeabilize the cell or if intracellular molecules are contaminating
the detergent solutions.

7. Vary the ATP in the relaxing solution/activation solution. That ATP may be causing
competitive inhibition.
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